Literature DB >> 31603187

Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.

Sara Sabbagh1, Adriana Almeida de Jesus2, SuJin Hwang3, Hye Sun Kuehn3, Hanna Kim4, Lawrence Jung5, Ruy Carrasco6, Sergio Rosenzweig3, Raphaela Goldbach-Mansky2, Lisa G Rider7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31603187      PMCID： PMC6821280          DOI： 10.1093/brain/awz293

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  11 in total

1.  Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.

Authors:  Kazuhiro Kurasawa; Satoko Arai; Yumeko Namiki; Ayae Tanaka; Yuta Takamura; Takayoshi Owada; Masafumi Arima; Reika Maezawa
Journal:  Rheumatology (Oxford)       Date:  2018-12-01       Impact factor: 7.580

2.  Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment.

Authors:  Drew J B Kurtzman; Natalie A Wright; Janice Lin; Alisa N Femia; Joseph F Merola; Mital Patel; Ruth Ann Vleugels
Journal:  JAMA Dermatol       Date:  2016-08-01       Impact factor: 10.282

3.  Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.

Authors:  Siamak Moghadam-Kia; Devon Charlton; Rohit Aggarwal; Chester V Oddis
Journal:  Rheumatology (Oxford)       Date:  2019-06-01       Impact factor: 7.580

4.  Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.

Authors:  Norimoto Kobayashi; Shunichiro Takezaki; Ichiro Kobayashi; Naomi Iwata; Masaaki Mori; Kazushige Nagai; Naoko Nakano; Mari Miyoshi; Noriko Kinjo; Takuji Murata; Kenji Masunaga; Hiroaki Umebayashi; Tomoyuki Imagawa; Kazunaga Agematsu; Shinji Sato; Masataka Kuwana; Masafumi Yamada; Shuji Takei; Shumpei Yokota; Kenichi Koike; Tadashi Ariga
Journal:  Rheumatology (Oxford)       Date:  2014-10-06       Impact factor: 7.580

5.  Development of a Validated Interferon Score Using NanoString Technology.

Authors:  Hanna Kim; Adriana A de Jesus; Stephen R Brooks; Yin Liu; Yan Huang; Rachel VanTries; Gina A Montealegre Sanchez; Yaron Rotman; Massimo Gadina; Raphaela Goldbach-Mansky
Journal:  J Interferon Cytokine Res       Date:  2018-04       Impact factor: 2.607

6.  JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.

Authors:  Leandro Ladislau; Xavier Suárez-Calvet; Ségolène Toquet; Océane Landon-Cardinal; Damien Amelin; Marine Depp; Mathieu P Rodero; Denisa Hathazi; Darragh Duffy; Vincent Bondet; Corinna Preusse; Boris Bienvenu; Flore Rozenberg; Andreas Roos; Claudia F Benjamim; Eduard Gallardo; Isabel Illa; Vincent Mouly; Werner Stenzel; Gillian Butler-Browne; Olivier Benveniste; Yves Allenbach
Journal:  Brain       Date:  2018-06-01       Impact factor: 13.501

7.  Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis.

Authors:  Manami Kato; Kei Ikeda; Takahiro Kageyama; Tadamichi Kasuya; Takashi Kumagai; Hiroki Furuya; Shunsuke Furuta; Tomohiro Tamachi; Akira Suto; Kotaro Suzuki; Hiroshi Nakajima
Journal:  J Clin Rheumatol       Date:  2021-12-01       Impact factor: 3.517

8.  2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Authors:  Lisa G Rider; Rohit Aggarwal; Angela Pistorio; Nastaran Bayat; Brian Erman; Brian M Feldman; Adam M Huber; Rolando Cimaz; Rubén J Cuttica; Sheila Knupp de Oliveira; Carol B Lindsley; Clarissa A Pilkington; Marilynn Punaro; Angelo Ravelli; Ann M Reed; Kelly Rouster-Stevens; Annet van Royen-Kerkhof; Frank Dressler; Claudia Saad Magalhaes; Tamás Constantin; Joyce E Davidson; Bo Magnusson; Ricardo Russo; Luca Villa; Mariangela Rinaldi; Howard Rockette; Peter A Lachenbruch; Frederick W Miller; Jiri Vencovsky; Nicolino Ruperto
Journal:  Arthritis Rheumatol       Date:  2017-04-06       Impact factor: 10.995

Review 9.  A Path to Prediction of Outcomes in Juvenile Idiopathic Inflammatory Myopathy.

Authors:  Ann Marie Reed; Cynthia S Crowson; Jeffrey Arthur Dvergsten
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

10.  Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.

Authors:  Charalampia Papadopoulou; Ying Hong; Ebun Omoyinmi; Paul A Brogan; Despina Eleftheriou
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501
View more
  15 in total

Review 1.  [Recent research on tofacitinib in the treatment of pediatric rheumatic diseases].

Authors:  Shi-Hai Zhou; Ya-Qun Xiong; Ya Chen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

Review 2.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

Review 3.  Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA).

Authors:  Emely L Verweyen; Grant S Schulert
Journal:  Rheumatology (Oxford)       Date:  2022-03-02       Impact factor: 7.046

4.  Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series.

Authors:  Matthew Shneyderman; Shivani Ahlawat; Lisa Christopher-Stine; Julie J Paik
Journal:  Rheumatology (Oxford)       Date:  2021-11-03       Impact factor: 7.580

Review 5.  Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.

Authors:  Tsz-Wing Yeung; Kai-Ning Cheong; Yu-Lung Lau; Kei-Chiu Niko Tse
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-30       Impact factor: 3.054

6.  Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.

Authors:  Hanna Kim; Fatima Gunter-Rahman; John A McGrath; Esther Lee; Adriana A de Jesus; Ira N Targoff; Yan Huang; Terrance P O'Hanlon; Wanxia L Tsai; Massimo Gadina; Frederick W Miller; Raphaela Goldbach-Mansky; Lisa G Rider
Journal:  Arthritis Res Ther       Date:  2020-04-06       Impact factor: 5.156

7.  Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report.

Authors:  Walter Conca; Ihab Weheba; Mohei-Eldin Abouzied; Abeer Abdelsayed; Yousif Aleyouni; Eid Al-Mutairy; Nasir Bakshi; Mohammad Khalid
Journal:  Front Pharmacol       Date:  2020-12-15       Impact factor: 5.810

8.  Human myelomeningocele risk and ultra-rare deleterious variants in genes associated with cilium, WNT-signaling, ECM, cytoskeleton and cell migration.

Authors:  K S Au; L Hebert; P Hillman; C Baker; M R Brown; D-K Kim; K Soldano; M Garrett; A Ashley-Koch; S Lee; J Gleeson; J E Hixson; A C Morrison; H Northrup
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

Review 9.  Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity.

Authors:  Peter D Burbelo; Michael J Iadarola; Jason M Keller; Blake M Warner
Journal:  Front Immunol       Date:  2021-03-08       Impact factor: 7.561

Review 10.  Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.

Authors:  Hanna Kim
Journal:  Curr Opin Rheumatol       Date:  2021-09-01       Impact factor: 4.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.